ISA to Present at Business Conferences in May 2022

27 Apr 2022

Oegstgeest, 27 April 2022 – ISA is pleased to announce that its representatives will be participating and presenting at the following business conferences in May 2022. If you would like to meet with our team at any of these events, please contact us through the conference partnering systems or via info@isa-pharma.com.

LSX World Leaders Congress

Date: 10-11 May 2022, London, UK

Panel Presentation by: Anton Mat, Director Business Development, ISA Pharmaceuticals

Title: Key Multi-Stakeholder Considerations In Early-Stage Commercial Deal-Making

Date & Time: Tuesday, 10 May 2022, 14.30pm BST

Bio€quity Europe

Date: 16-18 May 2022, Milan, Italy

Presentation by: Gerben Moolhuizen, Chief Executive Officer, ISA Pharmaceuticals

Date & Time:

Read more »

ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology

14 Apr 2022

AMPLIVANT® adjuvant technology has the potential to increase vaccine immune response 10 – 100 foldModi-1 clinical trial to begin in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer

Oegstgeest, The Netherlands, 14 April 2022 – ISA Pharmaceuticals today announces that a clinical trial using ISA’s novel AMPLIVANT® adjuvant technology has started. The trial, run by partner Scancell Holdings plc (AIM: SCLP, “Scancell”) is a multicentre clinical trial, testing the Moditope® vaccine Modi1. This first-in-human clinical trial brings Modi-1 to patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal

Read more »